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ABSTRACT
INTRODUCTION: Cervical cancer is almost entirely preventable through a combination of
vaccination, timely screening, and treatment. There is strong evidence that cervical cancer
screening services were disrupted during the COVID-19 pandemic; these disruptions may lead
to preventable increases in cases of high-grade squamous intraepithelial lesions of the cervix
(HSIL cases), cervical cancer cases, and cervical cancer deaths.
OBJECTIVE: The objective of this analysis was to offer insight into possible future trends in HSIL
cases, cervical cancer cases, and cervical cancer deaths.
METHODS: A model was built to simulate cervical cancer progression and was fit to data on
HSIL cases, cervical cancer cases, and cervical cancer deaths reported in 2008 and 2016. A
disruption due to COVID-19 that reduced screening based on a range of plausible values was
introduced into the model and the impact on cases of HSIL, cervical cancer, and cervical cancer
deaths was observed.
RESULTS: A substantial increase in total HSIL cases (combined undetected and detected),
cervical cancer cases, and cervical cancer deaths may be expected due to this disruption (4.2%,
6.7%, and 4.9%, respectively, in the next 5 years). However, the number of detected HSIL cases
may decrease (-3.4%), potentially masking the true impact from medical providers and public
health practitioners.
CONCLUSIONS: There may be a decrease in detected HSIL cases in the coming years, but the
true number of HSIL cases is likely to increase, as are cervical cancer cases and cervical cancer
deaths. Results could inform efforts to reach patients who missed screening and aid in
interpretation of surveillance and registry data in coming years.
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INTRODUCTION
Cervical cancer is caused by human papillomavirus (HPV) (Schiller & Davies, 2004).
Disease progresses from infection, through cervical lesions and precancer, to cancer. At each
stage, screening can be utilized to detect infection, lesions, precancer, and cancer. At later
stages, treatment can prevent progression (Schiller & Davies, 2004). Vaccination and screening
make cervical cancer a nearly preventable disease (Schiller & Davies, 2004). Multiple different
systems of classification for cervical lesions exist, but for the purposes of this study, we will use
low-grade and high-grade squamous intraepithelial lesions to distinguish the stages of HPV
progression. Infection and cervical intraepithelial lesion grade 1 (CIN 1) are considered lowgrade squamous intraepithelial lesions (LSIL); CIN 2, CIN 3, and adenocarcinoma in situ (AIS) are
considered high-grade squamous intraepithelial lesions (HSIL).
There is strong evidence that cervical cancer prevention services have been disrupted
during the COVID-19 pandemic due to factors such as reduced provider capacity, loss of
employment and insurance, stay-at-home orders, etc. (Miller et al., 2021). These disruptions
may lead to increases in cervical cancer in the coming years, and the type of services disrupted
will likely have an impact on future outcomes observed (Burger et al., 2021). For example,
significant lags in primary screening are projected to lead to fewer excess cervical cancer cases
compared to lags in surveillance (any non-routine screening or other follow-up of an abnormal
result, not including colposcopy or treatment), colposcopies, or excisional treatment after
abnormal screening results (Burger et al., 2021). Other work has demonstrated that simply
increasing practice capacity, although important, is insufficient to address missed screenings
and other related care (Gupta, Chauhan, Prinja, & Pandey, 2021). The people most at risk for

cervical cancer may not seek care for a variety of reasons, even once providers are able to see
patients at full capacity. For example, the number of people uninsured in the U.S. rose during
the pandemic (Bundorf, Gupta, & Kim, 2021), and lack of insurance is associated with delayed
or missed cervical cancer screening (Benavidez, Zgodic, Zahnd, & Eberth, 2021). Although there
have been demonstrated short-term impacts on cervical cancer screening during 2020 (Miller
et al., 2021), there may be long-term impacts that have yet to be documented.
Further complicating the reality of lags in cervical cancer screening and treatment are
disparities that exist at every stage of cervical cancer prevention. Access to obstetricians and
gynecologists, HPV vaccination, rates of screening, follow-up of abnormal screening results, and
treatment all differ by race/ethnicity (Wentzensen, Clarke, & Perkins, 2021). Those with better
access to care have better outcomes and lower incidence of cervical cancer (Wentzensen et al.,
2021). If the rates of screening, follow-up of abnormal screening results, or treatment have
been impacted differentially by race/ethnicity, future incidence of cervical lesions and cancer
are also likely to be differentially impacted and disparities may be exacerbated. These
disparities are important to explore and describe now to guide interventions that will bring
patients back into the clinic to be screened and treated.
The objective of this modeled scenario analysis is to offer insight into possible future
trends in HSIL cases, cervical cancer cases, and cervical cancer deaths. Results could inform
efforts to reach patients who missed screening and aid in interpretation of surveillance and
registry data in coming years.

METHODS
Markov model
A Markov model was chosen to simulate cervical cancer progression from HPV infection
and LSIL to HSIL, cervical cancer, then cervical cancer death. Markov models have previously
been used to study cervical cancer due to the progressive nature of cancer (Myers, McCrory,
Nanda, Bastian, & Matchar, 2000; Taguchi et al., 2020). The model was built in R 4.1.0 to
simulate the progression of HPV infection (categorized as LSIL in the model) to cervical cancer.
The model includes compartments for normal, undetected LSIL, detected LSIL, undetected HSIL,
detected HSIL, undetected cancer, detected cancer, and cancer death (Figure 1). Five age
groups were included in the model: ages 18-20, 21-24, 25-29, 30-39, and over 40 years of age.
Each age group had slightly different compartments and structures based on the natural history
of HPV, cervical lesions, and cancer (Figure 1). At the first timestep, initial prevalence estimates
were determined randomly based on a multinomial distribution. At each subsequent timestep,
a percentage of the population entered and exited each compartment at deterministic rates
and the estimated prevalence for each category was based on the count in each compartment.
A “burn in” period of 1000 years was used to allow the model to reach equilibrium before
further analysis was conducted.
Vaccination was accounted for by using two separate iterations of the model, each with
50% of the population, one representing unvaccinated women and the other representing
vaccinated women. The vaccinated women had 80% lower likelihood of progressing to LSIL
from normal, to represent the approximate real-world effectiveness of the vaccines (e.g., to

account for those who receive only part of the series). In the vaccinated population, vaccination
began in 2008, 12 years before COVID disruptions were introduced.
Model output of the number of HSIL cases, cervical cancer cases, and cervical cancer
deaths using baseline parameter estimates was compared to 2008 and 2016 estimates. Profile
likelihood estimation was conducted to find the parameters that yielded the output closest to
reality (see “Profile likelihood estimation”). All model and analysis code can be found on Github
at https://github.com/guinevere-oliver/hpv_markov.

Population and prevalence estimates
The population to be included in the model was determined based on the number of
women in the United States aged 18-20, 21-24, 25-29, 30-39, and over 40 years old from the
2010 Census ("ACS 1-Year Estimates Subject Table S0101,"). For the purposes of this analysis,
“women” was used as a proxy for “people with cervices” (regardless of gender), the true
population of interest. Population estimates can be found in Table 1.
Prevalence of high-grade lesions in 2008 and 2016 was based on nationwide prevalence
estimates by McClung et al (2019), which were based on reported counts of HSIL cases from
five surveillance sites across the United States. Cervical cancer incidence and death were based
on data from the Surveillance, Epidemiology, and End Results Program (SEER, 2022a).

Elliptical compartments represent people with undetected (uncounted) cervical precancer or cancer. Rectangular compartments represent
people with detected (counted) cervical precancer or cancer. Values for the rates in the figure can be found in Tables 1-3.

Figure 1. Underlying structure of the Markov model.

Table 1. Yearly Parameters for Population by Age
Symbol
-----

Code
pop_size_1
pop_size_2
pop_size_3
pop_size_4

Meaning
Population size of women aged 18-24 in the U.S.
Population size of women aged 25-29 in the U.S.
Population size of women aged 30-39 in the U.S.
Population size of women aged 40 in the U.S.
Proportion of women aging into the model
age_in
𝒃
(turning 18)
𝝉1
age_up_0
Proportion of women turning 21
𝝉2
age_up_1
Proportion of women turning 25
𝝉3
age_up_2
Proportion of women turning 30
𝝉4
age_up_3
Proportion of women turning 40
Proportion of women aged 18-24 dying from
die_1
𝝁𝟏
unrelated causes
Proportion of women aged 25-39 dying from
die_2_3
𝝁𝟐
unrelated causes
Proportion of women aged  during from
die_4
𝝁𝟒
unrelated causes
Proportion of women aged 20-29 who
𝜽𝟏
hyst_1
receive hysterectomies
Proportion of women aged 30-39 who
hyst_2
𝜽𝟐
receive hysterectomies
Proportion of women aged 40 who
𝜽𝟒
hyst_3
receive hysterectomies
Note: “Women” in this case is used as a proxy for “people with cervices.”

Value
14683822
10201392
19939084
74037377

Original Source
("ACS 1-Year
Estimates
Subject Table
S0101," 2010)

0.05
0.33
0.25
0.20
0.10

Calculated

7.4e-4
1.64e-3

(Murphy, 2018)

1.5e-2
1.0e-3
4.1e-3

(Adam et al.,
2022)

3.6e-2

Cervical cancer progression, treatment, screening, hysterectomy, and mortality estimates
Because progression of HPV infection through cervical lesions to cancer is typically only
observed at intermittent screenings, estimates for rates of progression were based on a small
number of peer-reviewed studies that have systematically observed progression over time
(Table 2) (Bekos et al., 2018; Elbasha, Dasbach, & Insinga, 2008; Insinga, Dasbach, & Elbasha,
2009; Malagón et al., 2018; Myers et al., 2000; SEER, 2022b; Taguchi et al., 2020). A baseline
estimate for each yearly rate of progression was determined by averaging the rate of
progression among several studies. Estimates for treatment, based on the proportion of

Table 2. Yearly Parameters for Natural History of Cervical Cancer by Age
Symbol
𝜶𝟎,𝟏

Code
norm_ulsil_0

Meaning
Value
Original Source(s)
Proportion of women aged 18-20 0.15
progressing from normal to LSIL
𝜶𝟏,𝟏
norm_ulsil_1
Proportion of women aged 21-24 0.08
progressing from normal to LSIL
norm_ulsil_2
Proportion of women aged 25-29 0.02
𝜶𝟐,𝟏
(Malagón et al., 2018;
progressing from normal to LSIL
Myers et al., 2000)
𝜶𝟑,𝟏
norm_ulsil_3
Proportion of women aged 30-39 0.01
progressing from normal to LSIL
norm_ulsil_4
0
𝜶𝟒,𝟏
Proportion of women aged 40
progressing from normal to LSIL
𝜶𝟏,𝟐
ulsil_norm_1
Proportion of women aged 18-24 0.60
(Bekos et al., 2018; Insinga
regressing from LSIL to normal
et al., 2009; Myers et al.,
ulsil_norm_2_3
0.40
𝜶𝟐,𝟐
Proportion of women aged 25
2000; Taguchi et al., 2020)
regressing from LSIL to normal
ulsil_uhsil_1
Proportion of women aged 18-24 0.14
𝜷𝟏,𝟏
progressing from LSIL to HSIL
(Bekos et al., 2018;
𝜷𝟐,𝟏
ulsil_uhsil_2_3 Proportion of women aged 25-39 0.30
Elbasha et al., 2008;
progressing from LSIL to HSIL
Myers et al., 2000;
Taguchi et al., 2020)
𝜷𝟒,𝟏
ulsil_uhsil_4
0.30
Proportion of women aged 40
progressing from LSIL to HSIL
𝜷𝟏,𝟐
uhsil_ulsil_1
Proportion of women aged 18-24 0.62
regression from HSIL to LSIL
(Bekos et al., 2018;
uhsil_ulsil_2_3 Proportion of women aged 25-39 0.35
𝜷𝟐,𝟐
Elbasha et al., 2008;
regression from HSIL to LSIL
Myers et al., 2000;
Taguchi
et al., 2020)
𝜷𝟒,𝟐
uhsil_ulsil_4
0.30
Proportion of women aged 40
regression from HSIL to LSIL
𝜸𝟐
uhsil_ucan_2_3 Proportion of women aged 25-39 6e-5
(SEER, 2022b)
progressing from HSIL to cancer
𝜸𝟒
uhsil_ucan_4
12e-5
Proportion of women aged 40
(SEER, 2022b)
progressing from HSIL to cancer
𝝁𝒄
dcan_dcandeath Proportion of women with cancer 0.35
(SEER, 2022b)
dying from cancer
Note: These parameters are the same in the undetected and detected compartments of the model.
“Women” in this case is used as a proxy for “people with cervices.”

Table 3. Yearly Parameters for Cervical Precancer and Cancer Screening and Treatment by Age
Symbol

Code

Meaning

𝝎𝟏

ulsil_dlsil

Proportion of women with undetected
LSIL who are screened to detected LSIL

𝝎𝟐

uhsil_dhsil

Proportion of women with undetected
HSIL who are screened to detected HSIL

Proportion of women with undetected
ucan_dcan
cancer who are screened to detected
𝝎𝟑
cancer
Proportion of women with detected LSIL
dlsil_uhsil
who are lost to follow up and progress to
𝝆𝟏
undetected HSIL
Proportion of women with detected HSIL
𝝆𝟐
dhsil_ucan who are lost to follow up and progress to
undetected cancer
Proportion of women with detected HSIL
dhsil_norm
who are treated to normal (based on %
𝝈𝟏
treated and treatment success rate)
Proportion of women with detected
dcan_norm cancer who are treated to normal (based
𝝈𝟐
on treatment success rate)
Note: “Women” in this case is used as a proxy for “people with cervices.”

Value
0.28 at
baseline;
variable
0.28 at
baseline;
variable
0.28 at
baseline;
variable
0.06 at
baseline;
variable
0.06 at
baseline;
variable
0.81

0.5

Original
Source(s)

(Benavidez et
al., 2021;
Klabunde et
al., 2012)

Calculated

(Mishra,
Pimple, &
Shastri, 2011)

women treated with high grade lesions or cancer times treatment success rate, were also taken
from the published literature (Mishra, Pimple, & Shastri, 2011). Screening estimates were based
on the percentage of women reporting adherence to the 2018 United States Preventive Task
Force guidelines for cervical cancer (Benavidez et al., 2021). Hysterectomy rates were based on
estimates calculated from the Behavioral Risk Factor Surveillance System (Adam, White, &
Saraiya, 2022), and mortality data was taken from the United States National Center for Health
Statistics (Murphy, 2018). All parameters and sources can be found in Table 2 and Table 3.

Profile likelihood estimation
A function encompassing the model was created and estimates for the number of
detected HSIL cases, detected cervical cancer cases, and cervical cancer deaths were generated,
along with a summary log likelihood that compared each of these estimates to the actual 2008
estimates. A range of age-specific estimates for norm_ulsil, ulsil_norm, ulsil_uhsil, and
uhsil_ulsil were input into the function. Most estimates for the age groups 18-20, 21-24, 25-29,
and 30-39 years old did not generate clear log likelihood maxima, and therefore the best
estimate based on the values input (often an extreme of the input values) was chosen for these
age groups. However, estimates for the age group over 40 years old did yield clear maxima, and
the estimates generating the maximum log likelihood for this age group were chosen for the
model. Level of vaccination was adjusted to best fit the 2016 estimates.

Analysis
Several analyses were conducted to assess the impact of COVID-19 on HSIL cases,
cervical cancer cases, and cervical cancer deaths. First, the model was run with a 40%, 60%, and
80% decrease in screening (and concomitant increase in loss to follow-up) during the year 2020,
with screening and loss to follow-up returning to baseline after 1 year. A cubic spline function
was fit to each resultant line, and the results of the model were compared to baseline (no
disruption) by integrating under each line and subtracting the “no disruption” baseline from the
estimates that included the disruption (Table 5). The model was also separated by
race/ethnicity (different population counts, screening rates, and vaccination rates; see Table 4).

Table 4. Parameters Varying by Race/Ethnicity
Race/ethnicity

Code

Meaning
Value
Proportion of women in the U.S.
perc_race
who identify as non-Hispanic
0.61
White (used to adjust population)
White
non-Hispanic
Proportion of women screened for
screen
0.80
cervical cancer in a typical year
vax
Proportion of women vaccinated
0.60
Proportion of women in the U.S.
perc_race who identify as non-Hispanic Black 0.12
(used to adjust population)
Black
non-Hispanic
Proportion of women screened for
screen
0.84
cervical cancer in a typical year
vax
Proportion of women vaccinated
0.45
Proportion of women in the U.S.
perc_race
who identify as Hispanic (used to
0.17
adjust population)
Hispanic
Proportion of women screened for
screen
0.80
cervical cancer in a typical year
vax
Proportion of women vaccinated
0.50
Note: “Women” in this case is used as a proxy for “people with cervices.”

Original Source
(Table P2: Hispanic or
Latino, and Not Hispanic
or Latino by Race, 2020)
(Benavidez et al., 2021)
(Boersma, 2020)
(Table P2: Hispanic or
Latino, and Not Hispanic
or Latino by Race, 2020)
(Benavidez et al., 2021)
(Boersma, 2020)
(Table P2: Hispanic or
Latino, and Not Hispanic
or Latino by Race, 2020)
(Benavidez et al., 2021)
(Boersma, 2020)

In the race/ethnicity analysis, the model was run three times, each with the race/ethnicityspecific parameters and a 60% decrease in screening and concomitant increase in loss to followup. The race/ethnicity models were also compared to baseline, although differences in absolute
counts were not included because the population counts by race were vastly different due to
differences in population size (Table 6).

RESULTS
Overall results
If COVID-19 had not disrupted cervical cancer screening, 426,000 HSIL cases (184,000
detected), 40,000 cervical cancer cases (10,000 detected), and 3,500 cervical cancer deaths

would be expected in the U.S. in 2020. A short-term disruption in screening is likely to lead to
long-term overall increases in all categories. In the next five years, these increases are expected
to be substantial. Over the next thirty years, the additional cases attributable to the COVID-19
disruption in screening are expected to continue to accumulate. However, the prevalence of
HSIL cases, cervical cancer cases, and cancer deaths is expected to return to baseline by
approximately the year 2030.

Undetected and detected HSIL cases
If screening for cervical cancer decreased by 60% for one year in 2020, there would be
an expected 4.2% increase in total HSIL cases in the next five years (both undetected and
detected), associated with an additional 89,000 cases attributable to disruptions in screening
during the pandemic (Table 5, Figure 2). The increase in total HSIL cases may range from 59,000
cases (2.8%) to 120,000 cases (5.6%) depending on the percentage decrease in screening (40%
to 80% decrease; Table 5, Figure 3). Over the next thirty years, the percentage above baseline is
expected to decline each year as the number of cases returns to normal, although the absolute
number of total excess cases is expected to increase over the same time frame, representing
diminishing effects of the pandemic disruptions over time (Table 5, Figures 2 and 3).
Detected HSIL cases are expected to decrease in the next five years due to the
disruption in screening (Table 5, Figures 2 and 3). Although the number of detected cases is
expected to increase slightly in two to five years, there is an overall expected decrease of 3.4%
(-2.3% to -4.5%, depending on screening), or 31,000 fewer detected cases in the next five years
(21,000 – 41,000 fewer detected cases). These decreases are expected to subside over the next
thirty years, with a net decrease of 0.47% (25,000 fewer detected cases; Table 5, Figure 2).

Figure 2. Cases of HSIL, cervical cancer, and cancer death.
The first vertical dashed line represents when the HPV vaccine became available in the United States
(2008). The second vertical dashed line shows the beginning of the COVID-19 pandemic (2020), when
the majority of disruptions to cervical cancer screening occurred.

Table 5. Absolute and Percent Change Estimates – 40%, 60%, and 80% Decrease in Screening

Type of Cases
HSIL (undetected and
detected)
HSIL (detected only)
Cancer (undetected and
detected)
Cancer (detected only)

Cancer deaths

Absolute Change (% Change)
Time frame
40% decrease

60% decrease

80% decrease

2020-2025

59,000 (2.8%)

89,000 (4.2%)

120,000 (5.6%)

2020-2050

69,000 (0.55%)

100,000 (0.83%)

140,000 (1.1%)

2020-2025

-21,000 (-2.3%)

-31,000 (-3.4%)

-41,000 (-4.5%)

2020-2050

-17,000 (-0.31%)

-25,000 (-0.47%)

-34,000 (-0.63%)

2020-2025

8,800 (4.4%)

13,000 (6.7%)

18,000 (8.9%)

2020-2050

13,000 (1.1%)

19,000 (1.7%)

26,000 (2.2%)

2020-2025

1,900 (3.9%)

2,800 (5.8%)

3,800 (7.7%)

2020-2050

3,100 (1.1%)

4,600 (1.6%)

6,100 (2.2%)

2020-2025

560 (3.3%)

850 (4.9%)

1,100 (6.6%)

2020-2050

1,100 (1.1%)

1,600 (1.6%)

2,200 (2.2%)

Undetected and detected cancer cases and cancer deaths
Both detected cancer and total cancer (detected and undetected) are expected to
increase in the next five years (Table 5, Figures 2 and 3). Detected cancer is expected to
increase by 5.8% (3.9% - 7.7%), resulting in an additional 1,900 to 3,800 cases (Table 5, Figures
2 and 3). Total cancer is expected to see even greater increases, a 6.7% (4.4% - 8.9%) increase in
the next five years and 13,000 (8,800 – 18,000) additional cases (Table 5, Figures 2 and 3).
Cancer death is expected to increase by 4.9% in the next five years (3.3% - 6.6%), with 850
additional deaths due to cervical cancer (560 – 1,100; Table 5, Figures 2 and 3). Like HSIL and
cancer cases, although the percentage increase in cancer and cancer deaths is expected to go
down in the next thirty years, the absolute number of additional cases is expected to increase.
By 2050, prevalence all types of cases are expected to return to baseline.

Figure 3. Range of cases of HSIL, cervical cancer, and cancer death.
The first vertical dashed line represents when the HPV vaccine became available in the United States
(2008). The second vertical dashed line shows the beginning of the COVID-19 pandemic (2020), when
the majority of disruptions to cervical cancer screening occurred. The light red shading shows a range of
possible values for cases and deaths, based on a 40% decrease in screening and increase in loss to
follow-up (low range estimate) through an 80% decrease in screening and increase in loss to follow-up
(high range estimate).

Race/ethnicity-stratified analysis
When stratified by race/ethnicity (White non-Hispanic, Black non-Hispanic, and
Hispanic), the same patterns hold true across racial/ethnic categories: total HSIL cases, cervical
cancer cases, and cervical cancer deaths are expected to increase, whereas detected HSIL cases
are expected to decrease. However, the percentage change differs between racial/ethnic
categories. White non-Hispanic women and Hispanic women are expected to have a slightly
higher increase in total HSIL cases compared to Black non-Hispanic women (Table 6, Figure 4).

Table 6. Percent Change Estimates by Race/Ethnicity

Type of Cases

Time frame

White
non-Hispanic
% Change

Black
non-Hispanic
% Change

Hispanic
% Change

HSIL (undetected and
detected)

2020-2025

4.4%

4.1%

4.4%

2020-2050

0.88%

0.81%

0.86%

2020-2025

-3.5%

-3.4%

-3.6%

2020-2050

-0.49%

-0.47%

-0.51%

2020-2025

6.4%

6.7%

6.4%

2020-2050

1.6%

1.7%

1.6%

2020-2025

5.6%

5.8%

5.5%

2020-2050

1.6%

1.6%

1.6%

2020-2025

4.7%

5.0%

4.7%

2020-2050

1.6%

1.5%

1.6%

HSIL (detected only)
Cancer (undetected
and detected)
Cancer (detected only)

Cancer deaths

The first vertical dashed line represents when the HPV vaccine became available in the United States (2008). The second vertical dashed line
shows the beginning of the COVID-19 pandemic (2020), when the majority of disruptions to cervical cancer screening occurred.

Figure 4. Cases of HSIL, cervical cancer, and cancer deaths by race/ethnicity.

Hispanic women are expected to have the largest decrease in detected HSIL compared to
baseline (Table 6, Figure 4). Black non-Hispanic women are expected to have the largest
increases in cancer cases (both detected cancer and total cancer), and in the next five years are
expected to see the highest increase in cancer deaths (6.7%; Table 6, Figure 4). However, White
non-Hispanic and Hispanic women are expected to have the largest increase in cancer deaths
over the next thirty years (1.6%; Table 6, Figure 4).

Ratio of HSIL cases to cervical cancer cases over time
Changes in screening may lead to changes in the ratio of HSIL cases to cervical cancer
cases over time. The expected ratio without disruptions to screening is about 19:1. The
introduction of vaccination briefly decreased this ratio because vaccination prevents infection
but does not impact later stages of cervical cancer development. However, as vaccination takes

Figure 5. Ratio of HSIL cases to cancer cases over time.
The black line represents the approximate expected ratio of HSIL cases to cancer cases with no
disruption in screening due to COVID-19. The red line represents the approximate expected ratio with a
disruption in screening due to COVID-19.

effect, the ratio is expected to return to approximately 19:1. Disruptions in screening, however,
may have an impact on this ratio. If screening is disrupted, there will be fewer detected HSIL
cases. Cervical cancer detection is unlikely to be as severely impacted as HSIL detection due to
cancer symptoms and the likelihood of continued surveillance after abnormal screening results,
even during the pandemic. The ratio may have decreased to about 15:1 during 2020, but will
likely return to 19:1 between 2030 and 2040.

DISCUSSION
Impact of COVID-19 disruptions
Even a one-year disruption in cervical cancer screening could result in substantial
increases in total HSIL cases, cervical cancer cases, and cervical cancer deaths in the coming
years. Notably, there will likely be an initial apparent decrease in HSIL cases due to fewer
people being screened (and thus fewer cases being detected and reported). However, the true
number of HSIL cases is likely to increase in that same period. This decrease in detection of HSIL
cases could deter efforts to bring women back into the clinic if screening disruptions are not
appropriately considered.
Even a 40% decrease in screening and increase in loss to follow-up over the course of
one year could lead to tens of thousands of additional HSIL cases, thousands of additional
cervical cancer cases, and hundreds of additional cervical cancer deaths. Although the model
cannot be directly applied to subsets of the population, it is reasonable to assume that regions
where disruptions were longer or more intense can expect to see a larger impact on future
cases of HSIL, cervical cancer, and cervical cancer death. If a 60% or 80% decrease in screening

and concomitant increase in loss to follow-up occurred, we can expect to see even more
substantial short- and long-term impacts.
The race/ethnicity-stratified analysis demonstrates one way in which these increases are
likely to be unequally distributed across the population. Based on differences in screening rates
and vaccination status alone, there were differences in the impact of COVID-19 among
populations of different race/ethnicity. While non-Hispanic White women and Hispanic women
are projected to see the highest increases in total HSIL cases and long-term increases in cervical
cancer death, non-Hispanic Black women are expected to see the greatest increases in cervical
cancer cases and the greatest short-term increases in cervical cancer death. These differences
highlight disparities that may worsen in coming years if appropriate resources are not directed
to those populations most at-risk for cervical cancer.
The ratio of HSIL cases to cervical cancer cases may be a useful indicator for surveillance
over time. If there is a substantial dip in the ratio during and after 2020, it could be an
indication that HSIL cases are not being detected. As the ratio returns to 19:1, the expected
ratio, this may be an indicator that cases are being detected at the pre-pandemic rate.

Limitations
This model and analysis have several limitations that should be considered when
interpreting results. First, the model is based on population estimates, and individual women
may have different chances of progression or regression based on other factors (e.g., immune
function, age at sexual debut, etc.). If those characteristics are associated with likelihood of
being screened or lost to follow-up, this could bias model results. Furthermore, the vaccination
introduced in the model in 2008 is not a dynamic term, but rather stays the same over time. In

reality, HPV vaccination rates have been increasing in most populations since the vaccine was
introduced. Screening recommendations and rates have also changed over time, so the
assumption that screening rates would be exactly the same between 2008 and 2016 (the years
the model was fit to) is another potential limitation.
In the race/ethnicity-stratified model, only “White non-Hispanic,” “Black non-Hispanic,”
and “Hispanic” are included, because those populations have the most reliable and current
documentation and data available. However, this leaves out many people who may have a
different experience associated with their race/ethnicity. Notably, the separation of “Hispanic”
from “White” and “Black” leaves out possible intersectional effects, for example differences
between Hispanic women who identify as White compared to Hispanic women who identify as
Black. Furthermore, the analysis only accounts for differences in population size, screening rate,
and vaccination rate among women of different race/ethnicities. Other differences, such as
mortality rate, hysterectomy rate, insurance status, healthcare access, differential impact of
COVID-19, etc., are also likely to impact cervical lesions, cancer, and cancer death, but
differences in these categories by race/ethnicity are not accounted for in this model.
Finally, because the parameters are yearly, the disruption to screening and increase in
loss to follow-up was addressed at a year level. Therefore, the nuances of significant decreases
in the early months of 2020, followed by a possible rebound in later months (approximated by
about a 60% overall decrease) are not captured. Although the range of a 40% to 80% decrease
in screening and increase in loss to follow-up attempts to acknowledge uncertainty in the
disruption, some clinics may have experienced much smaller disruptions, whereas others may
have completely closed their doors to patients for months. This type and level of heterogeneity

is not captured in the model. Furthermore, because disruptions are considered on a population
level, heterogeneity in screening is also lost. Some women may have been screened almost
immediately when screening became available again, whereas others may not get screened for
multiple screening cycles after missing one in 2020.
Overall, the model should be considered an indicator of possible future patterns, but
exact numbers should be interpreted with caution, and may not accurately predict outcomes in
sub-populations.

Future directions and conclusions
In coming years, there may be a decrease in detected HSIL cases, but the true number of
HSIL cases is likely to increase, as are cervical cancer cases and cervical cancer deaths. Although
the increases are unlikely to be indicative of a permanent trend, they could impact tens of
thousands of women and lead to hundreds of excess deaths due to an almost completely
preventable cancer. These disruptions need to be addressed directly, and patient outreach
should be conducted to minimize the impact of COVID-19 on screening.
This outreach may be conducted by individual providers or by provider networks. For
example, the Kaiser Permanente healthcare system credits its quick rebound in cervical cancer
screening rates to a robust system of notifications and reminders for routine medical care,
including screening (Miller et al., 2021). Organizations or programs such as the National Breast
and Cervical Cancer Early Detection Program could also play a role in reminding people to be
screened, especially those who are uninsured or underinsured, the primary target of the
program ("National Breast and Cervical Cancer Early Detection Program (NBCCEDP)," 2021).
There are also opportunities for structural change, for example the authorization and

distribution of at-home testing kits for high-risk HPV types, or other forms of at-home
screening. Prior to the pandemic, screening compliance has been shown to increase when athome test kits are available (Giorgi Rossi et al., 2015).
Future work should go beyond race/ethnicity when stratifying this type of analysis.
Insurance coverage, employment status, location, income, and gender identity are all known to
impact cervical cancer screening and are all factors that may have been differentially impacted
by the COVID-19 pandemic (Benavidez et al., 2021; Peitzmeier, Khullar, Reisner, & Potter,
2014). It would be prudent to assess the risk of other sub-populations, and to determine
whether there may be identifiable risk factors for missing screening due to the COVID-19
pandemic.
There is no one solution to finding and screening all people who missed cervical cancer
screenings during the pandemic. Rather, it will take a concerted effort that includes
partnerships between healthcare agencies, providers, non-profits, and governmental
organizations to tackle this issue and avoid preventable increases in HSIL cases, cervical cancer
cases, and cancer deaths in the future.
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